+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06051617

Evaluation of Seladelpar Versus Placebo for Primary Biliary Cholangitis with Compensated Cirrhosis and Its Effect on Clinical Outcomes

Led by Gilead Sciences · Updated on 2026-11-02

402

Participants Needed

218

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.

CONDITIONS

Brief Title

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here